4D Molecular Therapeutics (FDMT) Change in Acquisitions & Divestments (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $102.4 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $102.4 million, down 38.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $286.1 million (down 10.83% YoY), and the FY2025 annual result was $350.4 million, up 107.33% from the prior year.
• Change in Acquisitions & Divestments improved to $102.4 million in Q1 2026 per FDMT's latest filing, from $49.2 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $205.3 million in Q3 2022 and troughed at -$135.2 million in Q4 2022.
• A 5-year average of $55.5 million and a median of $55.5 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2025: Change in Acquisitions & Divestments sank 2803.88% in 2022, then surged 1027.88% in 2025.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at -$135.2 million in 2022, then soared by 121.09% to $28.5 million in 2023, then jumped by 130.72% to $65.8 million in 2024, then slipped by 25.24% to $49.2 million in 2025, then surged by 108.19% to $102.4 million in 2026.
• Business Quant data shows FDMT's Change in Acquisitions & Divestments at $102.4 million in Q1 2026, $49.2 million in Q4 2025, and $32.9 million in Q3 2025.